Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells.

ABSTRACT: Somatostatin receptors are a pivotal target for treatment of pancreatic neuroendocrine tumors (pNET), either with somatostatin analogues (SSA) or radiolabeled SSA. The highest affinity target for the most commonly used SSA is the somatostatin receptor type 2 (sst₂ ). An important factor that may complicate treatment efficacy, is the variable number of receptors expressed on pNETs. Gene expression is subject to complex regulation, in which epigenetics has a central role. In this study we explored the possible role of epigenetic modifications in the variations in sst₂ expression levels in two human pNET cell lines, BON-1 and QGP-1. We found upregulation of sst₂ mRNA after treatment with the epidrugs 5-aza-2'-deoxycyti

SUBMITTER: Veenstra MJ 

PROVIDER: S-EPMC5871078 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature